1. Home
  2. AMS vs IBIO Comparison

AMS vs IBIO Comparison

Compare AMS & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Shared Hospital Services

AMS

American Shared Hospital Services

HOLD

Current Price

$2.06

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Logo iBio Inc.

IBIO

iBio Inc.

N/A

Current Price

$2.02

Market Cap

16.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMS
IBIO
Founded
1980
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8M
16.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AMS
IBIO
Price
$2.06
$2.02
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.50
AVG Volume (30 Days)
11.4K
13.2M
Earning Date
11-13-2025
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$29,423,000.00
$500,000.00
Revenue This Year
$3.81
N/A
Revenue Next Year
N/A
$11.11
P/E Ratio
N/A
N/A
Revenue Growth
17.84
185.71
52 Week Low
$2.01
$0.56
52 Week High
$3.39
$6.89

Technical Indicators

Market Signals
Indicator
AMS
IBIO
Relative Strength Index (RSI) 42.13 58.11
Support Level $2.03 $1.86
Resistance Level $2.15 $2.13
Average True Range (ATR) 0.06 0.44
MACD 0.01 0.01
Stochastic Oscillator 15.75 36.44

Price Performance

Historical Comparison
AMS
IBIO

About AMS American Shared Hospital Services

American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.

About IBIO iBio Inc.

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Share on Social Networks: